Green Light Photo Selective Vaporization of the Prostate vs. Transurethral Resection of Prostate for Benign Prostatic Hyperplasia
Journal of Lasers in Medical Sciences,
Vol. 2 No. 4 (2011),
8 February 2012
,
Page 152-158
Abstract
INTRODUCTION: Green light photo selective vaporization of the prostate (PVP) is a minimally invasive method of treatment for clinical benign prostatic hyperplasia with fewer side effects. The aim of this study is to evaluate the safety, effectiveness and cost analysis of PVP compared with transurethral resection of prostate.
METHODS: A systematic search was done in Cochrane, TRIP database, MEDLINE, NHS EED, NIHR HTA, CRD, Health star database, Pro Quest, Psycoinfo and Google Scholar to find randomized control trials, systematic reviews and HTA reports. The searched keywords were Green light laser (PVP or KTP) and prostate. The cost analysis was done by the perspective of society and providers.
RESULTS: Complication rate in 12 included evidences ranged from 0-9.3%. The complication rate of TUR-P (Transurethral Resection of Prostate) was more than PVP. Changing in flow rate reducing residual urine, improving patients’ symptoms and QOL (Quality of life), and operative outcome length of operation varied from no significant to significant differences in favor of TURP. Unit cost in both social and provider view was significantly high in PVP in comparison with TURP. Increasing the number of patients did not change the cost analysis.
CONCLUSION: PVP is a safe method for treatment of clinical BPH, but there is a lack of evidence for the evaluation of effectiveness. Overall, the unit cost for PVP was significantly more than TURP; for this reason this method could not be conducted in very wide indications, because of high cost.
- laser vaporization
- ablation techniques
- health technology assessment
- benign prostatic hyperplasia.
How to Cite
References
Safarinejad MR. Prevalence of benign prostatic hyperplasia in a population-based study in Iranian men 40 years old or older. Int Urol Nephrol 2008; 40(4):921-31.
Murtagh J, Foerster V. Photoselective vaporization for benign prostatic hyperplasia. Ottawa: Canadian agency for drugs and technologies in health; 2006. (Issues in emerging health technologies; issue 95).
Medical device market report: Iran, quarter II 2011. Chichester: Espicom Business Intelligence; 2011. (Medical market intelligence reports).
US. Congress, office of technology assessment. Technology and structural unemployment: reemployment of disabled adults. OTA-ITE-250. Washington, DC: U.S. Government printing office; 1986. p.385.
Elliot R, Payne K. Essentials of economic evaluation in health care. London: Pharmaceutical Press; 2005.
Muening P. Cost effectiveness analysis in health a practical approach. 2nd ed. San Francisco: John Willy and Sons; 2008. p. 137-50.
Drummond MF, Sculpher MJ, Torrance GW, O’Brien BJ, Stoddart GL. Methods for the economic evaluation of health care programmes. 2nd ed. Oxford: Oxford University Press; 1997. p. 72.
Horasanli K, Silay MS, Altay B, Tanriverdi O, Sarica K, Miroglu C. Photoselective potassium titanyl phosphate (KTP) laser vaporization versus transurethral resection of the prostate for prostates larger than 70 mL: a short-term prospective randomized trial. Urology 2008; 71(2):247- 51.
Bouchier-Hayes DM, Anderson P, Van Appledorn S, Bugeja P, Costello AJ. KTP laser versus transurethral resection: early results of a randomized trial. J Endourol 2006; 20(8):580-5.
Ruszat R, Wyler SF, Seitz M, Lehmann K, Abe C, Bonkat G, et al. Comparison of potassium-titanyl-phosphate laser vaporization of the prostate and transurethral resection of the prostate: update of a prospective non-randomized two-centre study. BJU Int 2008; 102(10):1432-8.
Stafinski T, Menon D, Harris K, Md GG, Jhangri G. Photoselective vaporization of the prostate for the treatment of benign prostatic hyperplasia. Canadian Urological Association Journal 2008; 2(2): 124-34.
Alivizatos G, Skolarikos A, Chalikopoulos D, Papachristou C, Sopilidis O, Dellis A, et al. Transurethral photoselective vaporization versus transvesical open enucleation for prostatic adenomas >80ml: 12-mo results of a randomized prospective study. Eur Urol 2008; 54(2):427-37.
Skolarikos A, Alivizatos G, Chalikopoulos D, Papachristou C, Varkarakis I, Chrisofos M, et al. 80w PVP versus TURP: results of a randomized prospective study at 12 months of follow-up. J Urol 2008; 179(4): 628.
Sarrafzadeghan N, Boshtam M, Rafiei M. Risk factors for coronary artery disease in Isfahan, Iran: Eur J Public Health 1999; 9(1): 20-6.
Hajebrahimi S, Mahboub Ahari A, Sadeghi Ghyassi F, Mostafaie A, Yousefi M. Holmium Laser Prostate Enucleation (HOLEP) Versus Trans-Urethral Resection of Prostate (TURP) in Treatment of Symptomatic Prostatic Enlargement; A Health Technology Assessment. J Laser Med Sci 2011; 2(1):36-42.
- Abstract Viewed: 535 times
- PDF Downloaded: 368 times